The inherent challenge in CNS drug discovery is the uniqueness of the human brain and the consequently limited clinical relevance of animal models and lack of primary human cells available for use in in vitro assay systems. At Aquila, we understand that induced pluripotent stem cells (iPSC) are the first step in translating your CNS drug candidate from animal models to humans.
We offer a suite of tailored iPSC in vitro assays, working closely with you to develop custom human cell models for proof-of-concept (POC) and target validation assays specific for your therapeutic target. We can generate human CNS cells from both embryonic stem cells or disease specific iPSC’s that have physiologically relevant genetic background and disease-specific phenotypes, for use in both mono- and co-culture assay systems with tailored readouts, accelerating your best route to clinic.
Please get in touch to find out how we can support your iPSC study requirements.